Hypothesis: Some controversy exists concerning the appropriate surgical management for patients with thyroid cancer invading the laryngotracheal wall. We have used shaving of the wall when cancer invasion was confined to the perichondrium, and extensive resection when it invaded further. Preoperative assessment of the depth and length of laryngotracheal invasion is important when choosing an appropriate surgical procedure.
D IFFERENTIATED thyroid cancer usually has a good prognosis; however, it sometimes invades the adjacent organs and causes death by asphyxia. The practice of complete resection of malignant tumors has improved local control and survival rates. [1] [2] [3] [4] Among cases in which cancer spread, laryngotracheal extension has been reported in 35% to 60% of patients with locally invasive diseases. [5] [6] [7] Preoperative assessment of laryngotracheal invasion is important when choosing the appropriate treatment. The surgical procedures used currently include shaving of the laryngotracheal wall and extensive resection (fenestration, segmental tracheal resection, and partial or total laryngectomy). The choice of procedure depends on several variables, such as patient age, histological type, and depth and extent of invasion. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] We have applied shaving of the laryngotra-cheal wall for differentiated thyroid cancer invading the perichondrium and, when feasible, extensive resection for differentiated thyroid cancer with deeper invasion. Judging whether thyroid cancer invades deeper than the perichondrium of the trachea can be difficult to do during surgery. Therefore, it is important to make a correct preoperative assessment of the depth and length of laryngotracheal invasion.
We describe the cases in which we evaluated bronchoscopic findings of laryngotracheal invasion of thyroid cancer to predict the depth and length of invasion so that we could determine the appropriate surgical procedure. Although many reports 8, 14, [16] [17] [18] document the preoperative evaluation of laryngotracheal invasion by computed tomography, magnetic resonance imaging (MRI), or bronchoscopy, none of these has comprehensively addressed the issue of determining surgical procedures.
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RESULTS
According to the classification by Shin et al, 19 of 30 patients who underwent complete resections, 14 patients without laryngotracheal invasion were at stage 0. Four patients in whom cancer cells were detected in the shaved materials, although they showed no macroscopic residual tumors, were at stage I. Two patients were at stage II, 8 were at stage III, and 2 were at stage IV. Of these16 patients between stage I and stage IV, 14 
PATIENTS AND METHODS

PATIENTS
Between January 1, 2000, and July 30, 2000, 171 patients underwent surgery for thyroid cancer, and 16 (9.4%) of these had laryngotracheal invasion. There were 3 men and 13 women whose ages ranged from 33 to 84 years (mean, 60.8 years). The mean tumor size was 32.9 mm. We examined all 171 patients using MRI and ultrasonography (US). Selection criteria for bronchoscopy were based on either MRI or US findings. An unclear border between the thyroid tumor and the laryngotracheal wall or destruction of the laryngotracheal wall was defined as a positive sign of invasion. We suspected laryngotracheal invasion when deletion of the fat plane between the thyroid tumor and the laryngotracheal wall was seen. We used bronchoscopy to examine 37 patients in whom laryngotracheal invasion was diagnosed or suspected by MRI or US. Seven patients were excluded because complete resections of the thyroid tumor were not performed. Shaving of the laryngotracheal wall was performed in 4 patients in whom invasion was suspected during dissection; although bronchoscopic diagnosis in them was negative for laryngotracheal invasion. Extensive resection was performed in 12 patients in whom diagnosis by bronchoscopy indicated laryngotracheal invasion. Fourteen patients received no laryngotracheal resection because no invasion was found at operation. Other organs (the esophagus, the recurrent laryngeal nerve, or the strap muscle) were resected in 10 patients. Demographic data, tumor stage, surgical procedure performed, and bronchoscopic findings of 16 patients with laryngotracheal invasion are presented in the Table. BRONCHOSCOPY Bronchoscopic examination with a BF 1T30 endoscope (Olympus Co Ltd, Tokyo, Japan) was done with patients under local anesthesia. Localized mucosal redness, telangiectasia, mucosal elevation, mucosal edema, or mucosal erosion were considered the signs of invasion. Laryngotracheal invasion was diagnosed when at least 1 of these mucosal changes was seen. Diffuse mucosal redness and telangiectasia caused by compression were not considered positive signs. In 30 patients, the preoperative bronchoscopic diagnosis was compared with pathological results.
PATHOLOGICAL STAGING
We adopted the pathological staging system for laryngotracheal invasion by thyroid cancer as reported by Shin et al 19 (stage 0, no invasion; stage I, invasion limited to the external perichondrium; stage II, invasion between the rings or destroyed the cartilage; stage III, invasion extending through or between the cartilage into the lamina propria of tracheal mucosa; stage IV, tracheal mucosal invasion) (Figure 1 ).
(REPRINTED) ARCH SURG/ VOL 136, OCT 2001 cancers, 1 had follicular cancer, and 1 had anaplastic cancer.
The diagnostic usefulness of bronchoscopy was evaluated by stages. Because of the lack of localized mucosal changes, no stage I patients were diagnosed as showing invasion. In contrast, all patients in stages II, III, and IV were correctly diagnosed as having laryngotracheal invasion. Typical bronchoscopic images from each stage are shown in Figure 2 . Of 4 patients with stage I tumors, none showed localized mucosal changes of the larynx and trachea regardless of tumor compression. In 12 patients with tumors at stages II, III, or IV who required extensive resection, localized mucosal changes were always present in various degrees. Localized mucosal redness was seen in all patients with or without compression, and telangiectasia was occasionally seen in patients at each stage. Mucosal edema, elevation, and erosion were occasionally seen in patients at stages III and IV.
All patients with complete resections (except 1 patient with anaplastic cancer who died 5 months after surgery) were alive without recurrence at the time of this study.
COMMENT Differentiated thyroid cancer usually has a good prognosis, particularly if the tumor is confined to the gland. Invasion of adjacent organs makes the prognosis unfavorable. 1, 8, 20, 21 Laryngotracheal invasion is common, ac-counting for 35% to 60% of all locally invasive diseases, [5] [6] [7] and it has been reported to occur in 3.7% to 12.4% of all thyroid cancers. [8] [9] [10] 18, [22] [23] [24] Although complete resection of a malignant tumor improves local control and survival rate, 1-4 appropriate indications for either shaving the laryngotracheal wall or extensive resection for the laryngotracheal invasion is controversial. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 18, 20, [25] [26] [27] Czaja et al 6 have applied extensive resection of thyroid cancers invading the laryngotracheal mucosa or submucosa, and shaving of the laryngotracheal wall for tumors invading only the laryngotracheal perichondrium. Several groups have agreed to this indication for determining surgical procedures. 7,10-12, 16 We also have applied these indications because we ascertained a cancer-free margin by intraoperative pathological diagnosis. Other groups did not advocate shaving of the laryngotracheal wall, but they did not discuss the depth of cancer invasion. Only Park et al 18 concluded that extensive resection should be performed even if thyroid cancer invaded only the perichondrium.
To our knowledge to date, this is the first study to evaluate the bronchoscopic invasive signs of thyroid cancer by focusing on its depth and length as preoperative indicators for choosing an appropriate surgical treatment. Computed tomography scanning and MRI are useful for massive intraluminal involvement of thyroid cancer, but they seem to be of limited use for examining the depth and length of laryngotracheal invasion. Some authors have reported the usefulness of bronchoscopy for tracheal invasion with esophageal cancer. [28] [29] [30] [31] Esophageal cancer invades the trachea from the posterior wall that lacks cartilage. Thyroid cancer usually invades the trachea between the rings of the cartilage. Therefore, the invasive signs of esophageal cancer on bronchoscopy cannot simply be applied as an invasive sign of thyroid cancer. Localized mucosal change is an important sign of laryngotracheal invasion, especially localized mucosal redness. In stage I patients, the only mucosal change is diffuse mucosal redness caused by compression. In patients at stages II, III, and IV, localized mucosal redness always exists at various degrees, and this redness is stronger than that caused by compression. Histologically, the trachea consists of 4 layers: epithelium, lamina propria of mucosa, tracheal cartilage, and adventitia. The lamina propria of mucosa, which occupies a wide area under the epithelium and extends between the rings of the cartilage, is rich in blood and lymph vessels. Disturbance of blood and lymph flow by injury to the lamina propria induces mucosal changes such as redness, telangiectasia, and edema. Injury of the lamina propria by a large thyroid nodule is caused by strong compression on the tracheal cartilage, causing congestion and lymphostasis in the lamina propria, and resulting in diffuse mucosal changes. The injury to the lamina propria by thyroid cancer usually occurs between the rings of the cartilage, and only the invaded area shows congestion and lymphostasis resulting in localized mucosal changes.
Bronchoscopy is useful as a preoperative procedure for determining the appropriate surgical strategy for thyroid cancer invading the laryngotracheal wall.
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